This present invention relates to novel Lubiprostone crystals and methods for preparing the same. The preparation methods provided by the invention can effectively reduce or eliminate impurity in the obtained Lubiprostone crystals.

A system for the crystallization of a substance to be crystallized which is dissolved in a solvent, comprising a crystallization apparatus which is flowed through by a solution to be concentrated which has the substance to be crystallized dissolved therein, and by a heating steam or a heating liquid, wherein the crystallization apparatus has at least one flow passage conducting the solution to be concentrated, at least one flow passage conducting the heating steam or the heating liquid, and at least one flow passage conducting vaporous solvent, wherein a respective flow passage conducting the solution to be concentrated is at least partly separated from a respective flow passage conducting the heating steam or the heating liquid by a steam-impermeable and liquid-impermeable wall and wherein a respective flow passage conducting the solution to be concentrated is at least partly separated from a respective flow passage conducting the vaporous solvent by a membrane wall permeable to the vaporous solvent, but not to the liquid solvent, wherein the crystallization apparatus is configured such that the solution to be concentrated is boiled in the respective flow passage conducting the solution to be concentrated and vaporous solvent produced during the boiling moves through the membrane wall into the adjacent flow passage conducting the vaporous solvent.

The present invention relates to a process for the preparation of Trisodium (4-{[(1S.3R)-1-([1,1-biphenyl]-4-yl-methyl)-4-ethoxy-3-methyl-4-oxobutyl]amino}-4-oxo butanoate)-(N-pentanoyl-N-{[2-(1H-tetrazol-1-id-5-yl)[1,1-biphenyl]-4-yl]methyl}-L-valinate) represented by the following structural formula-1:

##STR00001##

The invention relates to a process of creating particles of controlled size by creating them in the interstitial regions in a batch, semi-continuous, or continuous liquid phase. The method comprises making solid particles comprising: adding a precursor material to a liquid carrier to form a liquid continuous phase, wherein the concentration of the precursor material is from about 5% to about 99% by weight of the continuous liquid phase; adding an inert phase into the liquid continuous phase of step a, resulting in an inert phase and continuous liquid phase mixture having a volume fraction of the inert phase of from about 30% to about 98% and inert phase domain size of about 0.2 to about 200 m; transforming the precursor material physically or chemically, resulting in the formation of solid particles.

The present invention refers to new amorphous and crystalline solid forms of desvenlafaxine, also known as O-desmethylvenlafaxine or desmethylvenlafaxine, and to its salts, solvates, hydrates and polymorphs thereof, as well as to their use in the manufacture of a pharmaceutical composition useful in the treatment of depression and/or as a selective serotonin and norepinephrine reuptake inhibitor and also in menopause-associated vasomotor disorders.

A surfactant-assisted self-assembly method can be used to crystallize energetic materials with controlled morphology. Microparticles of hexanitrohexaazaisowurtzitane (CL-20) formed by this method may have enhanced functional reproducibility due to their monodisperse nature, and decreased shock sensitivity due to their sub-2 m particle size.

The present invention provides one method for the preparation of pharmaceutically acceptable chlorogenic acid, which comprises the following steps: a. Treating the sample aqueous solution; b. Freezing; c. Thawing and filtering; d. Treating the residue organic phase; e. Concentrating and crystallizing; f. Choosing the number of times to repeat steps a-e according to the variability of chlorogenic acid content in samples; g. Drying. If the chlorogenic acid extract is isolated and purified using this method, water-soluble impurities and liposoluble impurities can be well removed, that allows the impurity content of final products has fulfilled the requirements for medicine; meanwhile, the procedures of this method are simple, and organic solvents can be recycled for further use, with low cost. This method can be applied for the further isolation and purification of chlorogenic acid extract obtained by various ways, especially for the preparation of pharmaceutically acceptable chlorogenic acid.

Embodiments of the present disclosure provide a method for preparing a high-purity arabinose crystal, comprising operations of dissolving, blending, ion exchange, decolorization and filtration, fine filtration, evaporation and concentration, crystallization, centrifugation, and drying performed in sequence on a low-purity arabinose crystal. Throughout the operations of preparing the arabinose crystal, a pH value of a material may be controlled between 4.3 and 7.5, and a temperature may not exceed 70? C. This prevents arabinose from transforming into impurities under a high temperature, thereby maintaining and improving a purity of the prepared arabinose crystal.

The invention discloses a purification method, system and a detection method of N-methylmorpholine N-oxide (NMMO), and a N-methylmorpholine N-oxide obtained thereof. The NMMO is derived from a NMMO crude product prepared by the reaction of N-methylmorpholine with hydrogen peroxide. The mass concentration of NMMO in the NMMO crude product is 50% to 60%. The purification method includes: performing cooling crystallization to the NMMO crude product between ?20? C. and 78? C. to obtain crystalline NMMO. The NMMO purification method has a low cost, a high purity of the obtained NMMO product, and almost no generation of exhaust gas, waste water, and solid waste. Different from current NMMO purification process, the purification method of the invention does not require ion-exchange resin, thus completely solved problems of significant amount of wastewater with high concentration of salt and COD and spent ion-exchange resin caused by the regeneration of ion-exchange resin.

The present disclosure provides a preparation system and a preparation method for xylitol crystals. In the preparation system, outlets of a first centrifuge are connected with an inlet of a hot air drying tank and an inlet of a primary mother liquor storage tank through pipelines, respectively. Outlets of a second centrifuge are connected with an inlet of a second fluidized bed dryer and an inlet of a secondary mother liquor storage tank through pipelines, respectively. An outlet of a dicrystalline sugar dissolution tank is connected with an inlet of a blending tank through pipeline. An outlet of a tricrystalline sugar dissolution tank is connected with the inlet of the primary mother liquor storage tank. The blending tank is provided with an inlet for a raw material of xylitol hydrogenation solution. An output of an outlet of a first fluidized bed dryer is prepared xylitol crystals.